Consultant Gastroenterologist, St Marks Hospital, Harrow, Middlesex, UK.
Consultant Gastroenterologist, Western General Hospital, Edinburgh, UK.
Br J Hosp Med (Lond). 2021 Oct 2;82(10):1-11. doi: 10.12968/hmed.2021.0399. Epub 2021 Oct 26.
The 2021 National report from IBD UK included responses from over 10 000 patients with inflammatory bowel disease, over 70% of whom reported having at least one flare in the last 12 months. As the first-line treatment for patients with mild and moderate ulcerative colitis, the action and delivery mechanisms of mesalazine are crucial for successful management of the disease. The choice of the most appropriate formulation of mesalazine and securing patient concordance and adherence to treatment remains a challenge for healthcare professionals. This article details the outcome of a roundtable discussion involving a group of gastroenterology consultants and specialist nurses which considered the importance of ensuring that patients have individualised mesalazine therapy before escalation to other treatments and gives recommendations for the management of patients with mild or moderate ulcerative colitis.
IBD UK 发布的 2021 年国家报告共收到 10000 多名炎症性肠病患者的回复，其中超过 70%的患者报告称在过去 12 个月内至少有一次发作。美沙拉嗪是治疗轻度和中度溃疡性结肠炎的一线药物，其作用机制和输送机制对于成功治疗该疾病至关重要。选择最合适的美沙拉嗪制剂，并确保患者对治疗的一致性和依从性，仍然是医疗保健专业人员面临的挑战。本文详细介绍了一次圆桌讨论的结果，该讨论涉及一组胃肠病学顾问和专科护士，他们考虑了在升级为其他治疗方法之前确保患者接受个体化美沙拉嗪治疗的重要性，并为轻度或中度溃疡性结肠炎患者的管理提供了建议。
